Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study

Paul A. Hamlin; Ian W. Flinn; Nina Wagner-Johnston; Jan A. Burger; Greg P. Coffey; Pamela B. Conley; Glenn Michelson; Janet M. Leeds; Kenneth Der; Yvonne Kim; Alice Sabalvaro-Torres; Matt Birrell; Anjali Pandey; John T. Curnutte; Manish R. Patel

doi:10.1002/ajh.25387

Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study

Paul A. Hamlin, Ian W. Flinn, Nina Wagner-Johnston, Jan A. Burger, Greg P. Coffey, Pamela B. Conley, Glenn Michelson, Janet M. Leeds, Kenneth Der, Yvonne Kim, Alice Sabalvaro-Torres, Matt Birrell, Anjali Pandey, John T. Curnutte, Manish R. Patel

Leukemia

Research output: Contribution to journal › Letter › peer-review

25 Scopus citations

Original language	English (US)
Pages (from-to)	E90-E93
Journal	American journal of hematology
Volume	94
Issue number	4
DOIs	https://doi.org/10.1002/ajh.25387
State	Published - Apr 2019

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.25387

Cite this

Hamlin, P. A., Flinn, I. W., Wagner-Johnston, N., Burger, J. A., Coffey, G. P., Conley, P. B., Michelson, G., Leeds, J. M., Der, K., Kim, Y., Sabalvaro-Torres, A., Birrell, M., Pandey, A., Curnutte, J. T., & Patel, M. R. (2019). Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study. American journal of hematology, 94(4), E90-E93. https://doi.org/10.1002/ajh.25387

Hamlin, PA, Flinn, IW, Wagner-Johnston, N, Burger, JA, Coffey, GP, Conley, PB, Michelson, G, Leeds, JM, Der, K, Kim, Y, Sabalvaro-Torres, A, Birrell, M, Pandey, A, Curnutte, JT & Patel, MR 2019, 'Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study', American journal of hematology, vol. 94, no. 4, pp. E90-E93. https://doi.org/10.1002/ajh.25387

@article{e495c7ba6d75429cb8ddfbe93bb6132c,

title = "Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study",

author = "Hamlin, {Paul A.} and Flinn, {Ian W.} and Nina Wagner-Johnston and Burger, {Jan A.} and Coffey, {Greg P.} and Conley, {Pamela B.} and Glenn Michelson and Leeds, {Janet M.} and Kenneth Der and Yvonne Kim and Alice Sabalvaro-Torres and Matt Birrell and Anjali Pandey and Curnutte, {John T.} and Patel, {Manish R.}",

note = "Funding Information: This study was sponsored by Portola Pharmaceuticals, Inc. We thank the patients who participated in this study, as well as their families and the research staff at each site. Preparation of the manuscript was supported by Iwona Bucior, PhD, of Portola Pharmaceuticals, Inc. Data analysis was supported by Andreas Betz. Medical writing and editorial support were provided by Kimberly Brooks, PhD, CMPP, of SciFluent Communications, and were financially supported by Portola Pharmaceuticals, Inc.",

year = "2019",

month = apr,

doi = "10.1002/ajh.25387",

language = "English (US)",

volume = "94",

pages = "E90--E93",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies

T2 - Results of a phase I study

AU - Hamlin, Paul A.

AU - Flinn, Ian W.

AU - Wagner-Johnston, Nina

AU - Burger, Jan A.

AU - Coffey, Greg P.

AU - Conley, Pamela B.

AU - Michelson, Glenn

AU - Leeds, Janet M.

AU - Der, Kenneth

AU - Kim, Yvonne

AU - Sabalvaro-Torres, Alice

AU - Birrell, Matt

AU - Pandey, Anjali

AU - Curnutte, John T.

AU - Patel, Manish R.

N1 - Funding Information: This study was sponsored by Portola Pharmaceuticals, Inc. We thank the patients who participated in this study, as well as their families and the research staff at each site. Preparation of the manuscript was supported by Iwona Bucior, PhD, of Portola Pharmaceuticals, Inc. Data analysis was supported by Andreas Betz. Medical writing and editorial support were provided by Kimberly Brooks, PhD, CMPP, of SciFluent Communications, and were financially supported by Portola Pharmaceuticals, Inc.

PY - 2019/4

Y1 - 2019/4

UR - http://www.scopus.com/inward/record.url?scp=85059672928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059672928&partnerID=8YFLogxK

U2 - 10.1002/ajh.25387

DO - 10.1002/ajh.25387

M3 - Letter

C2 - 30592080

AN - SCOPUS:85059672928

SN - 0361-8609

VL - 94

SP - E90-E93

JO - American journal of hematology

JF - American journal of hematology

IS - 4

ER -

Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this